Microbot Medical Inc. (NASDAQ: MBOT) reported revenue and new customer growth of more than 100% in the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026, according to a company statement.

The company attributed the growth to the full market release of its LIBERTY Endovascular Robotic System, which commenced April 13, 2026. Health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania adopted the system during the quarter.

Health systems that had previously adopted the LIBERTY System during its limited market release also increased procedure volume in the second quarter, which the company said was due to site expansion and more users migrating to the system.

Microbot Medical expanded its U.S. sales territories from four to eight during the second quarter and said it plans to reach 12 territories by year-end. The company also said it intends to enter international markets before the end of 2026.

The company entered into an agreement with Lovell Government Services Inc. to serve federal healthcare systems, including the Veterans Health Administration, the Military Health System, and the Indian Health Service.

Microbot Medical received marketing clearance for the LIBERTY System from the Israeli Ministry of Health's AMAR Division, making Israel the first country outside the U.S. to approve the system, according to the company.

The company also said it entered into an agreement to establish a second manufacturing site to meet current and anticipated demand.